HC Wainwright Reaffirms “Buy” Rating for Barinthus Biotherapeutics (NASDAQ:BRNS)

HC Wainwright reissued their buy rating on shares of Barinthus Biotherapeutics (NASDAQ:BRNS) in a research report sent to investors on Tuesday,Benzinga reports. HC Wainwright currently has a $5.00 price target on the stock.

Separately, Alliance Global Partners reduced their price objective on Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating on the stock in a research note on Tuesday, August 13th.

Barinthus Biotherapeutics Stock Performance

Shares of BRNS opened at $0.89 on Tuesday. The company’s 50-day simple moving average is $1.26 and its 200-day simple moving average is $1.49. Barinthus Biotherapeutics has a 1 year low of $0.81 and a 1 year high of $4.16. The stock has a market capitalization of $35.38 million, a PE ratio of -0.60 and a beta of -0.59.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.23. The business had revenue of $14.97 million for the quarter. During the same quarter in the prior year, the firm posted ($0.37) earnings per share. On average, sell-side analysts predict that Barinthus Biotherapeutics will post -1.52 earnings per share for the current year.

Institutional Investors Weigh In On Barinthus Biotherapeutics

Several institutional investors have recently modified their holdings of BRNS. M&G Plc acquired a new stake in shares of Barinthus Biotherapeutics during the 2nd quarter worth about $7,276,000. Alphabet Inc. purchased a new stake in shares of Barinthus Biotherapeutics during the 2nd quarter worth approximately $2,119,000. DC Funds LP acquired a new position in shares of Barinthus Biotherapeutics in the 1st quarter valued at $1,528,000. BlueCrest Capital Management Ltd purchased a new position in shares of Barinthus Biotherapeutics in the 1st quarter valued at $1,292,000. Finally, Ipswich Investment Management Co. Inc. purchased a new position in shares of Barinthus Biotherapeutics in the 2nd quarter valued at $32,000. 25.20% of the stock is owned by hedge funds and other institutional investors.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.